hrp0094p2-147 | Diabetes and insulin | ESPE2021

Thrombocytopaenia induced by diazoxide treatment in a toddler with Hyperinsulinism-Hyperammonemia syndrome: a rare side-effect

Bisbinas Vasiliki , Giannopoulos Andreas , Karabouta Zacharoula ,

Introduction: Diazoxide is the first-line drug for Hyperinsulinemia-Hyperammonemia (HI/HA) syndrome, a disease due to a mutation in the glutamate dehydrogenase-1 (GLUD1) gene.Diazoxide, an opener of the pancreatic β-cells KATP-channels reducing insulin release, is uncommonly associated with thrombocytopaenia.Aim: We describe a toddler with HI/HA syndrome who developed thrombocytopaenia on diazoxide treatment.<p ...

hrp0095p2-174 | Growth and Syndromes | ESPE2022

Lysine urinary protein intolerance with lupus kidney, lupus brain and extremely short stature: a case report and literatures review

Huang Siqi , Hou Lele , Meng Zhe , Liang Liyang

Objective: To report the clinical and gene mutation characteristics of a patient with lysine urinary protein intolerance (LPI) characterized by lupus nephritis, lupus encephalitis and extreme short stature, so as to improve understanding of the clinical characteristics of LPI caused by SLC7A7 gene mutation.Methods: The clinical manifestation, laboratory examination and gene test results of a child with LPI diagnosed and ...

hrp0095p2-212 | Multisystem Endocrine Disorders | ESPE2022

Endocrinological Evaluation in a Case with WAGR Syndrome

Karacan Küçükali Gülin , Yeşil Şule , Aygün Arı Demet , Çetinkaya Semra , Bülbül Mehmet , Sezer Abdullah , Aycan Zehra , Toprak Şule , Savaş Erdeve Şenay

Introduction: WAGR syndrome was first described in 1964 by Miller et al. And is characterized by Wilms tumor, aniridia, genitourinary anomalies, and developmental delay. Endocrine/metabolic problems (obesity, dyslipidemia, hypertension, short stature), especially obesity, are seen in more than 70% of cases with WAGR syndrome. Here, we aimed to present a case with WAGR syndrome for endocrine evaluation.Case: A 12...

hrp0095p2-303 | Late Breaking | ESPE2022

Donohue syndrome in a Turkish infant: Mild clinical course despite severe genetic mutation

Tepe Derya , Kocaay Pinar , Cakir Gundogan Secil , Sirma Dokuzboy Refika , Boyraz Mehmet

Donohue syndrome(DS) is a rare and often lethal autosomal recessive disease. Its prevalence is estimated less than one in a million live births. Mutations in the insulin reseptor (INSR) gene cause rare severe INSR-related insulin resistance syndromes such as DS. It is characterized by severe insulin resistance (hyperinsulinemia, fasting hypoglycemia and postprandial hyperglycemia), intrauterine and postnatal growth retardation, hypotonia, organomegaly including heart, liver, k...

hrp0092p2-30 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

A Rare case of Neonatal Hypocalciuric Hypercalcemia Complicated with Arrhythmia

Arai Yuto , Okumura Ryo , Wada Soichiro , Haseyama Keiji , Sai Shuji

Background: Familial hypocalciuric hypercalcemia is a rare, lifelong, but benign hereditary disorder due to its mild, often asymptomatic phenotype. Here we present a rare case of neonatal hypocalciuric hypercalcemia complicated with arrhythmia.Case: A healthy male infant weighing 2636g was delivered by spontaneous vaginal delivery at term. The pregnancy had progressed normally, but neonatal arrhythmia was found by physic...

hrp0092p2-51 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Perinatal form Hypophosphatasia Caused by a Novel Large Duplication of ALPL Gene and two year follow-up under Enzyme Replacement Therapy; A case report

Hacihamdioglu Bulent , Ozgurhan Gamze , Pereira Catarina , Tepeli Emre , Acar Gulsen , Comert Serdar

Hypophosphatasia is a rare disease caused by mutations in the gene encoding tissue- nonspecific isoenzyme of alkaline phosphatase. Duplications of the ALPL gene account for fewer than 1% of the mutations causing HPP. It has been shown that asfotase alfa treatment mineralizes the skeleton and improves respiratory function and survival in severe forms of hypophosphatasia.The newborn was evaluated for respiratory failure and generalized hypoton...

hrp0092p2-82 | Diabetes and Insulin | ESPE2019

Thiamine Responsive Megaloblastic Anemia Syndrome with Restrictive Cardiomyopathy: A case report

Laimon Wafaa

Background: Thiamine-responsive megaloblastic anemia syndrome (TRMA), also known as Rogers syndrome, is characterized by megaloblastic anemia, sensorineural hearing loss, and diabetes mellitus. Disturbances of the thiamine transport into the cells results from homozygous mutation in the SLC19A2 gene. Rhythm disturbances and structural cardiac anomalies have been described in the syndrome.Case presentation: We report a bo...

hrp0092p3-50 | Diabetes and Insulin | ESPE2019

Hybrid Diabetes with Good Response to Metformin in an Adolescent with Polyglandular Polyendocrinopathy (APS2)

Hamed Noor , Soliman Ashraf

Introduction: Development of type 1 diabetes is well known in cases of type 2 autoimmune polyglandular syndrome (APS). We describe a case of APS2 who developed a hybrid form of diabetes that responded to metformin therapy.Case: The patient is a 17.5 year old male patient who has been diagnosed with APS2 at the age of 13 years with primary adrenal insufficiency and autoimmune hypothyroidism .he has been on treatment with ...

hrp0092p3-69 | Diabetes and Insulin | ESPE2019

An 8-Year-Old Boy with Down Syndrome who has had a History of Transient Hyperinsulinemia and was found to have Type 1 Diabetes During ALL Treatment

Nishimura Naoko , Iwanaga Kogoro , Kawai Masahiko

Case: An 8-year-old boy with Down syndrome. He was born at 36 week of gestation, birth weight was 1668 g (-2.5 SD). He complicated transient hyperinsulinemia (THI) treated with diazoxide for 2 months and hypothyroidism continuing treatment with levothyroxine. He was not detected transient abnormal myelopoiesis at neonatal period. He was diagnosed with precursor B-cell acute lymphoblastic leukemia (ALL) at age 8 years and started chemotherapy with a steroid, an...

hrp0092p3-162 | Growth and Syndromes (to include Turner Syndrome) | ESPE2019

Acromesomelic Dysplasia of Maroteaux- An Extremely Rare Cause of Short Stature

Chawla Meghna , Datar Chaitanya

Introduction: Acromesomelic Dysplasia of Maroteaux (AMDM) is a cause of severe short stature (final height below120cm) with shortening of the middle and distal segments of the limbs, caused by homozygous or heterozygous mutations in the NPR2 gene which encodes natriuretic peptide receptor B on chromosome 9p13Case report: The proband was 4y6mo old, second born to 3rd degree consanguineous parents and presented ...